Triple negative subtype
Study | Phase | Reference | Chemotherapy backbone | Experimental therapy | pCR |
---|---|---|---|---|---|
GEICAM/2006-03
| II | Alba E et al. [10] | EC × 4 followed by D × 4 | arm 1: D arm 2: D + Cb AUC 6 |
p = 0.61
|
GeparSixto
| II | von Minckwitz et al. [11] | wPac + NPLD + Bev for 18 weeks | arm 1: + Cb AUC 1.5 arm 2: − Cb |
p = 0.015
|
CALGB 40603
| II | Sikov WM et al. [12] | wPac × 12 followed by ddAC × 4 | arm 1: wPac arm 2: wPac + Bev arm 3: wPac + Cb AUC 6 × 4 arm 4: wPac + Bev + Cp |
p = 0.0029
|
WSG: ADAPT
| II | Gluz O et al. [13] | nab-Pac × 12 | arm 1: nab-Pac + Cb arm 2: nab-Pac + Gem |
p < 0.001
|
i-SPY 2
| Generic trial platform | Rugo H et al. [14] | wPac × 12 followed by ddAC × 4 | arm 1: wPac arm 2: wPac + pla A arm 3: wPac + pla B arm 4: wPac + Cp AUC 6 + Veli |
88% predicted probability
|
BRIGHTNESS
| III | Geyer CE et al. [15] | wPac × 12 followed by ddAC × 4 | arm 1: wPac + Cb AUC 6 + Veli arm 2: wPac + Cb + pla arm 3: wPac + pla + pla |
arm 1 vs arm 3: p < 0.001
arm 1 vs arm 2: p = 0.36
|